QHSLab Announces Major Research and Development Milestones for 2024: Doubling Assessment Completion and Advancing Digital Medicine Innovation
QHSLab, Inc. (OTCQB: USAQ) has announced significant R&D milestones for 2024, highlighting a doubling of assessment completions to approximately 50,000 year-to-date. The company's digital health platform is advancing AI-driven tools for improved clinical decision-making, focusing on allergy, depression, anxiety, and chronic pain. Two key abstracts have been accepted for presentation at the ACAAI conference, showcasing the platform's capabilities in allergy management and its connection to mental health outcomes. QHSLab has also submitted abstracts for the 2025 American Psychiatric Association Annual Meeting, exploring digital therapeutic interventions. Preliminary findings suggest lower levels of depression, anxiety, pain, and allergy scores among users of QHSLab's health journeys series.
QHSLab, Inc. (OTCQB: USAQ) ha annunciato importanti traguardi nella ricerca e sviluppo per il 2024, evidenziando un raddoppio delle conclusioni di valutazione a circa 50.000 dall'inizio dell'anno. La piattaforma di salute digitale dell'azienda sta sviluppando strumenti basati sull'AI per migliorare il processo decisionale clinico, concentrandosi su allergie, depressione, ansia e dolore cronico. Due importanti astrazioni sono state accettate per la presentazione alla conferenza ACAAI, mostrando le capacità della piattaforma nella gestione delle allergie e la sua connessione con i risultati della salute mentale. QHSLab ha anche presentato astrazioni per il Meeting Annuale dell'Associazione Americana di Psichiatria del 2025, esplorando interventi terapeutici digitali. I risultati preliminari suggeriscono livelli più bassi di depressione, ansia, dolore e punteggi allergici tra gli utenti della serie di percorsi di salute di QHSLab.
QHSLab, Inc. (OTCQB: USAQ) ha anunciado hitos significativos de I+D para 2024, destacando un duplicado de las finalizaciones de evaluación a aproximadamente 50,000 hasta la fecha. La plataforma de salud digital de la empresa está avanzando en herramientas impulsadas por inteligencia artificial para mejorar la toma de decisiones clínicas, enfocándose en alergias, depresión, ansiedad y dolor crónico. Dos resúmenes clave han sido aceptados para presentación en la conferencia ACAAI, mostrando las capacidades de la plataforma en la gestión de alergias y su conexión con los resultados de salud mental. QHSLab también ha presentado resúmenes para la Reunión Anual de la Asociación Americana de Psiquiatría de 2025, explorando intervenciones terapéuticas digitales. Los resultados preliminares sugieren niveles más bajos de depresión, ansiedad, dolor y puntuaciones de alergia entre los usuarios de la serie de viajes de salud de QHSLab.
QHSLab, Inc. (OTCQB: USAQ)는 2024년을 위한 중요한 연구 및 개발 이정표를 발표하며, 평가 완료 건수가 두 배로 증가하여 현재 약 50,000건에 이르렀다고 강조했습니다. 회사의 디지털 건강 플랫폼은 알레르기, 우울증, 불안 및 만성 통증에 초점을 맞춘 개선된 임상 의사 결정을 위한 AI 기반 도구를 개발하고 있습니다. 두 가지 주요 초록이 ACAAI 학회에서 발표하기로 허가되었습니다, 이는 알레르기 관리와 정신 건강 결과와의 연관성을 보여줍니다. QHSLab은 2025년 미국 정신의학회 연례 회의를 위해 디지털 치료 개입에 대해 조사하는 초록도 제출했습니다. 초기 발견은 QHSLab의 건강 여정 시리즈 사용자들 사이에서 우울증, 불안, 통증 및 알레르기 점수가 더 낮다는 것을 시사합니다.
QHSLab, Inc. (OTCQB: USAQ) a annoncé des jalons significatifs en R&D pour 2024, soulignant un doublement des finalisations d'évaluations à environ 50 000 depuis le début de l'année. La plateforme de santé numérique de l'entreprise développe des outils basés sur l'IA pour améliorer la prise de décision clinique, en se concentrant sur les allergies, la dépression, l'anxiété et la douleur chronique. Deux résumés clés ont été acceptés pour présentation lors de la conférence ACAAI, montrant les capacités de la plateforme dans la gestion des allergies et sa connexion aux résultats de santé mentale. QHSLab a également soumis des résumés pour la Réunion Annuelle de l'Association Américaine de Psychiatrie de 2025, explorant des interventions thérapeutiques numériques. Les résultats préliminaires suggèrent des niveaux plus bas de dépression, d'anxiété, de douleur et de scores d'allergie parmi les utilisateurs de la série de parcours de santé de QHSLab.
QHSLab, Inc. (OTCQB: USAQ) hat bedeutende Forschung- und Entwicklungsmeilensteine für 2024 angekündigt und hebt ein Doppeln der Abschlussbewertungen auf etwa 50.000 bis heute hervor. Die digitale Gesundheitsplattform des Unternehmens entwickelt KI-gestützte Tools zur Verbesserung der klinischen Entscheidungsfindung und konzentriert sich dabei auf Allergien, Depressionen, Angst und chronische Schmerzen. Zwei wichtige Abstracts wurden für die Präsentation auf der ACAAI-Konferenz akzeptiert, die die Fähigkeiten der Plattform im Allergiemanagement und deren Verbindung zu psychischen Gesundheitsergebnissen hervorheben. QHSLab hat auch Abstracts für die Jahrestagung der American Psychiatric Association 2025 eingereicht, die sich mit digitalen therapeutischen Interventionen beschäftigen. Vorläufige Ergebnisse zeigen niedrigere Werte bei Depressionen, Angstzuständen, Schmerzen und Allergiepunkten unter den Nutzern von QHSLabs Gesundheitsreisen-Serie.
- Doubled assessment completions to approximately 50,000 year-to-date
- Two abstracts accepted for presentation at the ACAAI conference
- Submitted two abstracts for the 2025 American Psychiatric Association Annual Meeting
- Preliminary findings show lower depression, anxiety, pain, and allergy scores among users
- None.
WEST PALM BEACH, FL, Sept. 17, 2024 (GLOBE NEWSWIRE) -- QHSLab, Inc. (the "Company") (OTCQB: USAQ), a leader in digital health and point-of-care technologies designed to empower clinicians with proactive, value-based healthcare solutions, today shared exciting updates on its Research & Development (R&D) activities, and patient outcomes for the year to date. The Company continues advancing healthcare technology by integrating AI-driven digital tools designed to improve clinical decision-making and patient care.
Year-to-date as of September 2024, QHSLab’s platform has processed approximately 50,000 assessments, more than doubling the number of assessments completed during the same period last year. This represents a meteoric rise in assessment completions with the Company quickly bringing the total number of completed assessments to the 100K milestone, supporting routine clinical use and ongoing research into allergy, depression, anxiety, and chronic pain.
"Our robust real-world data collection and innovative technologies have enabled us to drive meaningful improvements in patient outcomes, addressing both physical and mental health at the point of care," said Marcos Sanchez-Gonzalez, MD, PhD, VP of Medical & Scientific Affairs at QHSLab. "The significant progress we’ve made in understanding the link between allergic rhinitis and mental health conditions like anxiety and depression demonstrates our commitment to advancing holistic care solutions for the patients served by the medical practices we support through their use of our QHSLab platform."
Research & Development Initiatives
QHSLab’s R&D efforts remain focused on advancing digital medicine technologies that empower healthcare providers and enhance patient engagement. With a commitment to addressing chronic conditions like allergic rhinitis, anxiety, and depression, the Company continues to explore critical connections between mental and physical health.
"In 2024, our R&D program is pushing new boundaries in innovation. We are committed to reducing the non-clinical burden on providers while improving the overall patient experience and outcomes," said Troy Grogan, President and CEO of QHSLab. "The unprecedented growth in assessment completions this year underscores the value of our platform and its ability to drive impactful, data-driven care."
Publications, Abstracts, and Ongoing Research
QHSLab is proud to announce that two key abstracts have been accepted for presentation at the American College of Allergy, Asthma, and Immunology (ACAAI) conference in Boston next month. These abstracts showcase the unique capabilities of the QHSLab platform in allergy management and its connection to mental health outcomes:
- Longitudinal Study: The impact of help-seeking behaviors on allergic rhinitis and mental health outcomes
- Cross-Sectional Study: The association between poor allergy control and increased depression and anxiety symptoms
These studies, which are part of the Company’s enhanced real-world data capture capabilities, highlight significant findings linking allergic rhinitis to mental health outcomes, including improved SNOT-22 and PHQ-GAD16 scores for patients actively seeking care for their allergies and emotional well-being.
Additionally, QHSLab has submitted two abstracts for poster presentations at the 2025 American Psychiatric Association Annual Meeting, which focus on the Company’s latest digital therapeutic interventions for mental health and chronic pain. These abstracts explore the effectiveness of QHSLab’s digital platform in reducing symptoms of anxiety, depression, and chronic pain through integrated care. Preliminary findings suggest that users of the Company’s QHSLab health journeys series report lower levels of depression, anxiety, pain, and allergy scores after using the resources for just a few months. Although the findings are promising, the Company is not jumping to conclusions. The Company has ongoing R&D efforts to understand better the therapeutic potential of using the QHSLab health journeys resources - more to come.
Looking Ahead
QHSLab continues to leverage its vast real-world data and innovative digital platform to expand research on the interconnections between physical and mental health, exploring new avenues for delivering high-quality, patient-centered care. With more assessments being conducted daily and ongoing studies in allergy, anxiety, depression, and chronic pain, QHSLab remains at the forefront of transforming healthcare.
For more information about QHSLab and its digital health solutions, please visit qhslab.com.
About QHSLab, Inc.
QHSLab, Inc. (OTCQB: USAQ) is a medical device company providing digital healthcare solutions and point-of-care-diagnostic tests to primary care physicians. Digital healthcare allows doctors to assess patient responses quickly and effectively using advanced artificial intelligence algorithms. Digital healthcare can also remotely monitor patients’ vital signs and evaluate the effects of prescribed medicines and treatments on patients’ health through real-time data transferred from patient to doctor. QHSLab, Inc. also markets and sells point-of-care, rapid-response diagnostic tests used in the primary care practice. QHSLab, Inc.’s products and services are designed to help physicians improve patient monitoring and medical care while also improving their revenues.
Forward-Looking Statements
Certain matters discussed in this press release are ‘forward-looking statements’ intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company’s statements regarding trends in the marketplace, future revenues, future products, and potential future results and acquisitions are examples of such forward-looking statements. Forward-looking statements are generally identified by words such as ‘may,’ ‘could,’ ‘believes,’ ‘estimates,’ ‘targets,’ ‘expects,’ or ‘intends,’ and other similar words that express risks and uncertainties. These statements are subject to numerous risks and uncertainties, including, but not limited to, the timing of the introduction of new products, the inherent discrepancy in actual results from estimates, projections, and forecasts made by management, regulatory delays, changes in government funding and budgets, and other factors, including general economic conditions, not within the Company’s control. The factors discussed herein and expressed from time to time in the Company’s filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release. The Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Investor Relations Contact:
Olivia Giamanco
QHSLab, Inc.
(929) 379-6503
ir@usaqcorp.com
https://twitter.com/QHSLabInc
FAQ
What is QHSLab's stock symbol?
How many assessments has QHSLab processed in 2024?
What are the main focus areas of QHSLab's research?
Where will QHSLab present its research findings in 2024?
